1Strassburg CP, Marms MP. Therapy of autoimmune hepatitis. Best Pratt Res Clin Gastroenterol, 2011, 25: 673-687.
2Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis ofautoimmune hepatitis. J Hepatol, 1999, 31: 929-938.
3Hermes EM, Zeniya M, Czaja A J, et al. Simplified criteria for the diagnosis of antoimmune hepatitis. Hepatology, 2008, 48: 169-176.
4Czaja AJ. Performance parameters of diagnostic scoring systems for autoimmune hepatitis. Hepatology, 2008, 48: 1540-1547.
5Qiu D, Wang Q, Wang H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol, 2011, 54: 340-347.
6Mamas MP, Czaja A J, Gorham JD, et al. Diagnosis and management of autoimmane hepatitis. Hepatology, 2010, 51: 2193-2213.
7Czaja AJ. Features and consequences of untreated type I autoimmune hepatitis. Liver Int, 2009, 29: 816-823.
8Czaja Aft, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology, 2010, 139: 58-72.
9Wang Q, Qiu D, Ma X. Early normalization of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients. Aliment Pharmacol Ther, 2011, 34: 107-109.
10Kanzler S, Gerken G, Lhr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol, 2001, 34: 354-355.
9Hoffman MS,Mitchell GS.Spinal 5-HT7receptors and protein kinase A constrain intermittent hypoxia-induced phrenic long-term facilitation[J].Neuroscience,2013,250:632-643.
10Boberg KM,Wisloff T,Kjollesdal KS,et al.Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid[J].Aliment Pharmacol Ther,2013,38(7):794-803.
